Comprehensive Eye Cancer Website Meets Needs of Both Patients and Physicians

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 9
Volume 9
Issue 9

NEW YORK-Visitors to the Eye Cancer Network (ECN) website (www.eyecancer.com) can access a wealth of information on ocular cancers, including an extensive collection of clinical photographs (see images). The site is well designed, leading visitors logically and quickly to specific information and related links. For example, a visitor seeking information on retinal tumors easily finds the topic in the Eye Conditions index, where it is subdivided into retinoblastoma, retinal pigment epithelial tumors, retinal pigment epithelial hypertrophy, and von Hippel angioma.

NEW YORK—Visitors to the Eye Cancer Network (ECN) website (www.eyecancer.com) can access a wealth of information on ocular cancers, including an extensive collection of clinical photographs (see images). The site is well designed, leading visitors logically and quickly to specific information and related links. For example, a visitor seeking information on retinal tumors easily finds the topic in the Eye Conditions index, where it is subdivided into retinoblastoma, retinal pigment epithelial tumors, retinal pigment epithelial hypertrophy, and von Hippel angioma.

Webmaster Paul T. Finger, MD, is director of The New York Eye Cancer Center, which he established; director of the Ocular Tumor Service, The New York Eye and Ear Infirmary; and associate professor of ophthalmology, New York University School of Medicine. He is also principal investigator for the Collaborative Ocular Melanoma Study, sponsored by the National Institutes of Health and National Eye Institute.

The EyeCancer Network site is designed to meet the needs of both patients and physicians. Patients can seek out information on the eye and eye conditions written for the layperson, visit a frequently asked questions section, or search for a physician in the physician finder. But they also have access to the site’s wide array of clinical information, including sections on innovative treatments, NCI-funded studies, and ophthalmology meetings.

Of special interest is ECN Interactive, a bulletin board where patients can share their personal experiences in the “Heart 2 Heart” section, while physicians can discuss their clinical experiences in the “Eye 2 Eye” discussion forum.

Dr. Finger has also started the Online Journal of Ophthalmic Oncology (OJO), available on the ECN website. The journal will publish original laboratory and clinical investigations related to ophthalmic oncology. All manuscripts will be reviewed by a minimum of two specialists in ophthalmic oncology and/or related specialties, and accepted articles will be accessible to readers worldwide for a minimum of 1 year.

The Eye Care Foundation, established by Dr. Finger, is also featured on the website. The mission of this nonprofit organization is to provide up-to-date treatment information to patients and physicians, establish family and patient support programs, empower patients to find the resources they need, fund and direct research to find cures for eye diseases, and coordinate national and international prospective, randomized clinical trials to evaluate new methods of diagnosis and treatment.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content